3-(3-fluorobenzyl)-2-pyridone | 123566-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(3-fluorobenzyl)-2-pyridone
• 英文别名: 3-[(3-fluorophenyl)methyl]-1H-pyridin-2-one
• CAS: 123566-53-0
• 化学式: C₁₂H₁₀FNO
• 分子量: 203.216
• InChiKey: KANVWETWDNRLKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3-fluorobenzyl)-2-pyridone 在 <4-CH3OC6H4P(S)S>2 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以35%的产率得到3-(3-fluorobenzyl)pyridine-2-thione
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051
• 作为产物：
  描述：

  3-氰基吡啶 在 盐酸 、 叔丁基锂 、 乙酸酐 、 间氯过氧苯甲酸 、 汞 、 锌 作用下， 以 氯仿 为溶剂， 反应 33.0h， 生成 3-(3-fluorobenzyl)-2-pyridone
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051

文献信息

• 3-aralkyl-2-mercaptoyridines as dopamine-.beta.-hydroxylase inhibitors
  申请人：SmithKline Beckman Corporation

  公开号：US04839371A1

  公开（公告）日：1989-06-13

  Disclosed are novel substituted 3-aralkyl-2-mercaptopyridines of the structure: ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.

  揭示了新颖的结构为3-芳基基-2-巯基吡啶的取代物，其制备方法，制备中有用的中间体，含有它们的药物组合物以及它们在特定治疗中的用途，尤其是作为多巴胺-β-羟化酶抑制剂。
• Substituted pyridines as dopamine-beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0308159A2

  公开（公告）日：1989-03-22

  Compounds of formula in which X¹ to X⁵ are hydrogen, halogen, hydroxy or alkoxy and n is 1 to 5, processes for their preparation intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-β-hydroxylase inhibitors.

  式化合物 其中 X¹ 至 X⁵ 为氢、卤素、羟基或烷氧基且 n 为 1 至 5 的化合物、用于制备它们的中间体的制备工艺、含有它们的药物组合物以及它们在治疗中的用途，特别是作为多巴胺-β-羟化酶抑制剂。
• US4839371A
  申请人：——

  公开号：US4839371A

  公开（公告）日：1989-06-13